Clinical Trial Update: A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk [Phase 2]

View source ↗

Summary

A Phase 2, single-arm exploratory study evaluating the safety and efficacy of QL1706, a PD-1/CTLA-4 bispecific antibody, as neoadjuvant therapy in patients with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• QL1706

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection | Phase 2 | Status: NOT_YET_RECRUITING